reports
Coloplast A/S - Opdateret finanskalender 2025-26
Coloplast A/S - Opdateret finanskalender 2025-26 Venligst se vedlagte pdf. Opdatering af datoer i finanskalenderen Coloplast har opdateret datoerne i selskabets finanskalender vedrørende offentliggørelsen af årsregnskabet for 2025/26 samt afholdelsen af den ordinære generalforsamling 2026. De opdaterede datoer er som følger: Årsregnskabsmeddelelse for 2025/26 og Årsrapport 2025/26: ændret fra 5. november 2026 til 3. november 2026Ordinær generalforsamling 2026: ændret fra 3. december 2026 til 1. december 2026 For yderligere information og kalenderinvitationer til kommende beg...
Coloplast A/S - Updated Financial Calendar 2025-26
Coloplast A/S - Updated Financial Calendar 2025-26 Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General Meeting 2026. The updated dates are as follows: Financial Statements for the full year 2025/26 and Annual Report 2025/26: changed from November 5, 2026 to November 3, 2026Annual General Meeting 2026: changed from December 3, 2026 to December 1, 2026 For more information and calendar invitations for upcoming events, please visit: Kind...
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Julia Sundvall
- Oscar Lindquist
- ABGSC Healthcare Research
- Morten Larsen
- Konrad Zomer
- Thomas Zlowodzki
REL RELX PLC
DG VINCI SA
BNP BNP PARIBAS SA CLASS A
KNEBV KONE OYJ CLASS B
SK SEB SA
HNR1 HANNOVER RUECK SE
MMK MAYR-MELNHOF KARTON AG
CPG COMPASS GROUP PLC
KOMB KOMERCNI BANKA A.S.
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
WIZZ WIZZ AIR HOLDINGS PLC
ORSTED ORSTED
EZJ EASYJET PLC
ENEL ENEL SPA
RY4C RYANAIR HOLDINGS PLC
ASSA B ASSA ABLOY AB CLASS B
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
EMSN EMS-CHEMIE HOLDING AG
ANDR ANDRITZ AG
COLO B COLOPLAST A/S CLASS B
RIO RIO TINTO PLC
SNP PETROM S.A.
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
STLA STELLANTIS N.V.
LIN LINDE PUBLIC LIMITED COMPANY
AF AIR FRANCE - KLM
- Konrad Zomer
- Thomas Zlowodzki
REL RELX PLC
DG VINCI SA
BNP BNP PARIBAS SA CLASS A
KNEBV KONE OYJ CLASS B
SK SEB SA
HNR1 HANNOVER RUECK SE
MMK MAYR-MELNHOF KARTON AG
CPG COMPASS GROUP PLC
KOMB KOMERCNI BANKA A.S.
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
WIZZ WIZZ AIR HOLDINGS PLC
ORSTED ORSTED
EZJ EASYJET PLC
ENEL ENEL SPA
RY4C RYANAIR HOLDINGS PLC
ASSA B ASSA ABLOY AB CLASS B
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
EMSN EMS-CHEMIE HOLDING AG
COLO B COLOPLAST A/S CLASS B
RIO RIO TINTO PLC
SNP PETROM S.A.
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
STLA STELLANTIS N.V.
LIN LINDE PUBLIC LIMITED COMPANY
AF AIR FRANCE - KLM
- Oliver Metzger
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Julia Sundvall
- Oscar Lindquist
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - Regnskabsmeddelelse, Q1 2025/26
Coloplast A/S - Regnskabsmeddelelse, Q1 2025/26 2025/26 Delårsrapport, 1. kvartal 2025/261. oktober 2025 - 31. december 2026 Coloplast leverede i 1. kvartal en organisk vækst på 6% og en EBIT vækst1 i faste valutakurser på 3%. Den rapportede omsætning i danske kroner steg 0%, hvilket afspejler en negativ valutaeffekt på 4 procentpoint. Afkast af investeret kapital2 var på 15%. • Organisk vækst pr. område: Stomi 4 %, Kontinens 7 %, Stemme og Respiratorisk Pleje 8 %, Wound & Tissue Repair 5 % og Urologi 8 %.• Svag start i Stomi, som forventet, drevet af negativ vækst i Kina og høj baseli...
Coloplast A/S - Interim Financial Report, Q1 2025/26
Coloplast A/S - Interim Financial Report, Q1 2025/26 2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew 0%, reflecting 4%-points negative impact from currencies. Return on invested capital2 was 15%. • Organic growth rates by business area: Ostomy Care 4%, Continence Care 7%, Voice & Respiratory Care 8%, Wound & Tissue Repair 5%, and Interventional Urology 8% .• Soft start in Ostomy Care, as expected, driven by negative growth in China and a high...
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Julia Sundvall
- Oscar Lindquist
Coloplast A/S - Q1 2025/26 Earnings Release - Invitation for conferenc...
Coloplast A/S - Q1 2025/26 Earnings Release - Invitation for conference call on 6 Feb 2026 at 11.00am CET Friday, 6 February 2026 at 11:00-12:00am CETIn connection with the publication of Coloplast’s interim financial results for Q1 2025/26, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the e...
- ABGSC Healthcare Research
- Morten Larsen
Coloplast annoncerer ændringer i ledelsesteamet
Coloplast annoncerer ændringer i ledelsesteamet Coloplast offentliggør i dag ændringer til ledelsesteamet (ELT). Ændringerne omhandler Coloplasts urologiforretning og virksomhedens globale funktion for People & Culture. Leder af People & Culture, Dorthe Rønnau, har besluttet at forlade Coloplast for at starte et nyt kapitel i sin karriere. Dorthe Rønnau har haft forskellige roller på tværs af Coloplast-koncernen i næsten tre årtier. ”Coloplast har haft stor glæde af Dorthes værdier, integritet og stærke lederevner i hendes roller i Global Operations, Atos og People & Culture, og den øvers...
Coloplast announces changes to Executive Leadership Team
Coloplast announces changes to Executive Leadership Team Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group. “Dorthe’s values, integrity and strong leadership skills have benefitted the company across her roles in Global Op...
Skanska AB: 1 director
A director at Skanska AB maiden bought 5,000 shares at 251.350SEK and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025
Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025 I dag, den 4. december 2025, afholdt Coloplast A/S sin ordinære generalforsamling, hvor følgende beslutninger blev vedtaget: Årsrapporten for regnskabsåret 2024/25 blev godkendt.Forslag om udbetaling af udbytte for året på 18,00 kr. pr. aktie à nominelt 1 kr. blev godkendt. I tillæg til de 5,00 kr. pr. aktie à nominelt 1 kr., der blev udbetalt i forbindelse med Coloplast A/S’ halvårsresultat, bliver det samlede udbytte for regnskabsåret 2024/25 således 23,00 kr. pr. aktie à nominelt 1 kr.Vederlagsrapporten for regnskabsåre...
Coloplast A/S - Decisions at the Annual General Meeting 2025
Coloplast A/S - Decisions at the Annual General Meeting 2025 Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved.Distribution of year-end dividend of DKK 18.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2024/25 to DKK 23.00 per share of nominally DKK 1.The remuneratio...
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Julia Sundvall
- Oscar Lindquist
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.